Takeda
Takeda moves potential first-in-class diabetes drug into phase III
September 12, 2011Research and Development, Sales and Marketing TAK-875, Takeda, diabetes
Takeda has moved its potential first-in-class diabetes candidate TAK-875 into phase III clinical trials. The company hopes TAK-875 will offer …
NICE recommends Takeda’s cancer drug Mepact
September 7, 2011Sales and Marketing Mepact, NICE, Takeda
NICE has reversed its stance on Mepact and recommended the bone cancer drug after re-examining discounts and a new patient …
Takeda and Amylin stop obesity trial
August 8, 2011Research and Development, Sales and Marketing Amylin, Takeda
Takeda and Amylin have decided to halt further studies of its combination treatment for obesity, due to ‘evolving dynamics’ within …
Takeda forced to withdraw Actos in France
July 11, 2011Sales and Marketing Actos, Competact, Takeda, diabetes
Takeda has officially taken its diabetes drug Actos off the market in France at the request of the country’s medicines …
France pulls Takeda diabetes drugs after cancer fears
June 13, 2011Sales and Marketing Actos, Competact, EMA, Takeda
The French medicines agency has moved to prevent two Takeda diabetes drugs from being prescribed after fears they could increase …
Takeda buys Nycomed for $13.6bn
May 19, 2011Manufacturing and Production, Research and Development, Sales and Marketing Nycomed, Takeda
Takeda has acquired Swiss specialist pharma firm Nycomed, boosting its presence in emerging markets. The deal comes in at 9.6 …
Takeda denies $12bn Nycomed takeover reports
May 13, 2011Research and Development, Sales and Marketing Nycomed, Takeda
Japan’s biggest pharma firm Takeda has denied reports it is negotiating a billion dollar deal to acquire Swiss speciality firm …
Amgen’s novel lung cancer drug disappoints in phase III
April 1, 2011Research and Development Amgen, Millennium, NSCLC, Takeda, motesanib, non-small cell lung cancer
Amgen’s lung cancer drug motesanib has not meet its primary endpoint in a phase III study. The drug, developed in …
Takeda obesity drug falters at phase II
March 18, 2011Research and Development Alli, Amylin, Contrave, Meridia, Qnexa, Takeda, Xenical, lorcaserin, metreleptin, obesity, pramlintide
Yet another investigational drug appears to have faltered on the rocky path to develop anti-obesity treatments. Takeda Pharmaceutical Company and …
Takeda and Baxter make pandemic flu vaccine plans for Japan
December 7, 2010Manufacturing and Production Takeda, baxter, pharma manufacturing, vaccine manufacturing, vaccines
Takeda has made another move into the vaccines sector with the expansion of a deal with Baxter International for the …
Genzyme courting ‘white knight’ bid from Takeda
November 18, 2010Manufacturing and Production, Research and Development, Sales and Marketing Genzyme, Sanofi, Sanofi-Aventis, Takeda, pharma mergers
Genzyme is in talks with Takeda to secure a ‘white knight’ bid that would prevent Sanofi-Aventis from taking over the …
Anna Protopapas to lead Takeda’s global business development unit
October 21, 2010Sales and Marketing Anna Protopapas, Japanese pharma company, Takeda, appointment, sales and marketing
Takeda has set up a new global business development unit within its US subsidiary to oversee mergers, acquisitions and other …
NICE unmoved on Takeda bone cancer drug
October 13, 2010Sales and Marketing Mepact, NICE, Takeda
NICE has refused to recommend Takeda’s Mepact because of its “exceptionally high cost” and the “substantial uncertainty” about the osteosarcoma …
Pharma manufacturing news in brief
September 21, 2010Manufacturing and Production AAIPharma, Actavis, Japan, KV Pharmaceutical, Purac, Takeda, contract manufacturing
This week’s round-up of pharmaceutical manufacturing news includes updates from Takeda, KV Pharmaceutical, Actavis, AAIPharma and Purac, while Japan’s CMOs …
FDA launches safety review of Actos
September 20, 2010Sales and Marketing Actos, Takeda, diabetes
A new safety review of Takeda’s diabetes drug Actos has been launched by the FDA after a long-term study suggested …
Latest content
Aiforia deal to expand access to pathology AI
SMC accepts atogepant for acute migraine treatment in Scotland
New CCO Ogburn joins Cori Clinical
